Belay Diagnostics Reports Strong Clinical Utility for Summit 2.0
CHICAGO, July 21, 2026 Belay Diagnostics has announced the publication of a peer-reviewed clinical utility study demonstrating that its...
cerebrospinal fluid
Advertisement
Plus Therapeutics Partners with GTC to Expand CNSide Platform
HOUSTON & LAKE FOREST, Calif., July 16, 2026 Plus Therapeutics and Genomic Testing Cooperative (GTC) announced a strategic collaboration...
ProMIS Reports First Human PMN310 Evidence
CAMBRIDGE, Mass., July 14, 2026 ProMIS Neurosciences presented the first human evidence that its investigational Alzheimer’s disease therapy PMN310...
Plus Therapeutics Reinforces CNSide Clinical Value Following NCCN Guideline Update
HOUSTON, July 14, 2026 Plus Therapeutics highlighted updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for...
Vandria Reports Positive Phase 1 VNA-318 Data
LAUSANNE, Switzerland, July 13, 2026 Vandria announced new Phase 1 clinical data demonstrating that its investigational small molecule VNA-318...
Advertisements
Fujirebio Launches Automated pTau217 CSF Assay for Alzheimer’s Research
Tokyo, Japan – January 28, 2026 – Fujirebio, a global leader in in vitro diagnostics and part of H.U....
Advertisement
